Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Inovio progresses on RRP treatment, faces trial challenges and opportunities

Inovio Pharmaceuticals is making progress on INO-3107 and other pipeline candidates while managing financials and strategic trial design.
The company faces challenges in trial design, patient representation, and regulatory requirements but sees opportunities in market access and patient outcomes.
Overall, Inovio remains focused on advancing DNA medicine and delivering on key objectives for the benefit of patients.
Analysts' questions and executive responses indicate a thorough approach to addressing concerns and ensuring trial success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The biotech company announced a contract with the U.S. Department of Defense.

Why Inovio Pharmaceuticals Is Soaring Today

Inovio Pharmaceuticals Inc. (NASDAQ: INO) has announced that it received $71 million in funding from the U.S.

Why This Capital Injection Is Huge for Inovio

Shares of Inovio Pharmaceuticals Inc (NASDAQ: INO), which is developing a DNA vaccine for the novel coronavirus dubbed INO-4800, were advancing strongly Tuesday.

Inovio Rallies On DoD Funding For Coronavirus Vaccine Delivery Device

The biotech also said it will announce results from phase 1 testing of its COVID-19 vaccine candidate, INO-4800, by the end of June.

Inovio Wins $71 Million Department of Defense Contract for Its COVID-19 Vaccine Delivery Devices

NIKE

PayPal

Futures Reverse Higher Overnight

Shares of Inovio Pharmaceuticals Inc. INO, +7.21% gained 14.8% in premarket trading on Tuesday after it announced $71 million in funding from the Department of Defense to manufacture a handheld device that delivers its experimental COVID-19 vaccine.

Inovio shares jump on government funding for vaccine device

PLYMOUTH MEETING, Pa., June 23, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO) today announced it has received $71 million funding from the U.S. Department of Defense (DoD) to support the large-scale manufacture of the company's proprietary CELLECTRA® 3PSP smart device and the procurement of...

INOVIO Receives $71 Million Contract From U.S. Department of Defense To Scale Up Manufacture of CELLECTRA® 3PSP Smart Device and Procurement of CELLECTRA® 2000 for COVID-19 DNA Vaccine

Inovio Pharma's next clinical results will be a binary event for INO Stock. It will rise or fall based on its Phase 1 results due out by the end of June.

Inovio Pharma’s Next Clinical Results Will be Binary for INO Stock

With its coronavirus vaccine candidate facing slim chances of success, it's probably best to stay on the sidelines with INO stock.
The post Stay Safe on the Sidelines With Inovio Stock appeared first on InvestorPlace.

Stay Safe on the Sidelines With Inovio Stock

INO stock has been on a tear in recent months, but the shares may not necessarily make any new highs. Consider taking your profits now.

It’s Time to Take Your Profits From Choppy Inovio Stock

INO stock is up over 300% in 2020. But investors are going all in on the company's Covid-19 vaccine candidate, and that's still a gamble.

The Case for Buying Inovio Will Come Down to the Test Results

Inovio Pharmaceuticals Inc (NASDAQ: INO) shareholders are suing the company in U.S.

Inovio Faces Shareholder Lawsuit Over 3-Hour Coronavirus Vaccine Claim, Company Says DNA Medicine Misunderstood

Inovio is speeding toward a vaccine for the coronavirus and has plans to make 1 million doses by the end of the year to boost INO stock.
The post Inovio Stock Is Still a Strong Coronavirus-Related Bet to Make appeared first on InvestorPlace.

Inovio Stock Is Still a Strong Coronavirus-Related Bet to Make

AstraZeneca

Johnson & Johnson

Moderna

Pfizer

Some of the earliest novel coronavirus (COVID-19) vaccines to be approved are more likely to target prevention against developing severe symptoms from catching the virus, rather than the initial infection, multiple health experts told Bloomberg.

Early Coronavirus Vaccines Likely To Target Further Complications, Not Infection, Health Experts Say

Inovio has an attractive technical profile, but not very good fundamentals. Let's look at what bulls can utilize in INO stock.

Inovio Stock Still Has Strong Technicals – Here’s the Trade

INO stock is still attracting strong buying interest but investors may want to wait for the dust to settle first before adding shares.
The post Inovio Still a Hot Coronavirus Vaccine Supplier appeared first on InvestorPlace.

Inovio Still a Hot Coronavirus Vaccine Supplier

Inovio's COVID-19 vaccine face huge hurdles. INO stock will tread water until its manufacturing and financing issues are overcome.

Inovio Stock Will Tread Water Working on a Coronavirus Vaccine

Inovio Pharmaceuticals: Positioning For A Global Opportunity

The government probably won't help Inovio with its coronavirus vaccine and the company has other problems besides. Investors should sell INO stock.

The Odds For Long Shot Inovio Stock Just Got Longer

Between the government snubbing Inovio's vaccine and a legal dispute, INO stock is running into mounting headwinds.
The post Inovio Slumps as Its Setbacks Pile Up appeared first on InvestorPlace.

Inovio Slumps as Its Setbacks Pile Up

INO stock has its fair share of critics and under normal circumstances, those criticisms could cripple it. However, these are not normal circumstances.

Why Inovio Pharmaceuticals May Get a Pass on Coronavirus Vaccine Hype

INO stock has eased off the highs, but a major breakthrough could be just around the corner.
The post Why You Shouldn’t Rush to Take Profits on Inovio Stock appeared first on InvestorPlace.

Why You Shouldn’t Rush to Take Profits on Inovio Stock

The study is scheduled to start this month.

Inovio to Start a Phase 1/2 Study of its COVID-19 Vaccine in South Korea

Novavax

As companies race to produce a coronavirus vaccine, half of Americans may not be interested, and that haste may be part of the reason.

Could the Rush to a Vaccine Hurt Coronavirus Stocks?

SEOUL, South Korea and PLYMOUTH MEETING, Pa., June 4, 2020 /PRNewswire/ -- INOVIO (NASDAQ: INO), the International Vaccine Institute (IVI), and Seoul National University Hospital announced a partnership to start a Phase 1/2 clinical trial of INOVIO's COVID-19 vaccine INO-4800 in South...

INOVIO and IVI Partner with Seoul National University Hospital to Start Phase 1/2 Clinical Trial of INOVIO's COVID-19 DNA Vaccine (INO-4800) in South Korea

News for Inovio Pharmaceuticals Stock (INO)